Biomarkers: mining the biofluid proteome.
Proteomics has brought with it the hope of identifying novel biomarkers for diseases such as cancer. This hope is built on the ability of proteomic technologies, such as mass spectrometry (MS), to identify hundreds of proteins in complex biofluids such as plasma and serum. There are many factors that make this research very challenging beginning with the lack of standardization of sample collection and continuing through the entire analytical process. Fortunately the advances made in the characterization of biofluids using proteomic techniques have been rapid and suggest that these mainly discovery driven approaches will lead to the development of highly specific platforms for diagnosing diseases and monitoring responses to different treatments in the near future.
Veenstra
Timothy D
TD
Laboratory of Proteomics and Analytical Technologies, SAIC-Frederick, Inc., National Cancer Institute at Frederick, Frederick, MD 21702-1201, USA. veenstra@ncifcrf.gov
Conrads
Thomas P
TP
Hood
Brian L
BL
Avellino
Anthony M
AM
Ellenbogen
Richard G
RG
Morrison
Richard S
RS
D015415:Biomarkers / Q000097:blood / Q000134:cerebrospinal fluid / Q000652:urine; D001798:Blood Proteins / Q000032:analysis*; D006801:Humans; D020543:Proteome / Q000032:analysis*; D040901:Proteomics / Q000379:methods
D015415:Biomarkers; D001798:Blood Proteins; D020543:Proteome